A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials
Open Access
- 6 May 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (5) , 1432-1439
Abstract
Win statistics offer a new approach to the analysis of outcomes in clinical trials, allowing the combination of time-to-event and longitudinal measurements and taking into account the clinical importance of the components of composite outcomes, as well as their relative timing. We examined this approach in a post hoc analysis of two trials that compared dapagliflozin to placebo in patients with heart failure and reduced ejection fraction (DAPA-HF) and mildly reduced or preserved ejection fraction (DELIVER). The effect of dapagliflozin on a hierarchical composite kidney outcome was assessed, including the following: (1) all-cause mortality; (2) end-stage kidney disease; (3) a decline in estimated glomerular filtration rate (eGFR) of ≥57%; (4) a decline in eGFR of ≥50%; (5) a decline in eGFR of ≥40%; and (6) participant-level eGFR slope. For this outcome, the win ratio was 1.10 (95% confidence interval (CI) = 1.06–1.15) in the combined dataset, 1.08 (95% CI = 1.01–1.16) in the DAPA-HF trial and 1.12 (95% CI = 1.05–1.18) in the DELIVER trial; that is, dapagliflozin was superior to placebo in both trials. The benefits of treatment were consistent in participants with and without baseline kidney disease, and with and without type 2 diabetes. In heart failure trials, win statistics may provide the statistical power to evaluate the effect of treatments on kidney as well as cardiovascular outcomes.Keywords
This publication has 61 references indexed in Scilit:
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved TrialEuropean Journal of Heart Failure, 2023
- Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection FractionJAMA Cardiology, 2023
- Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time‐to‐event outcomesPharmaceutical Statistics, 2022
- Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trialEuropean Journal of Heart Failure, 2021
- Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialEuropean Journal of Heart Failure, 2021
- Evaluation of Kidney Function Throughout the Heart Failure Trajectory – A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2020
- The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline CharacteristicsEuropean Journal of Heart Failure, 2019
- A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)European Journal of Heart Failure, 2019
- Associations With and Prognostic Impact of Chronic Kidney Disease in Heart Failure With Preserved, Mid-Range, and Reduced Ejection FractionEuropean Journal of Heart Failure, 2017
- A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among componentsPharmaceutical Statistics, 2016